The report "Infectious Disease Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (Immunodiagnostics, PCR, NGS), Disease (Hepatitis, HIV, HAI, TB, Flu, Syphilis), End User (Labs)- Global Forecast to 2030", is projected to reach USD 42.20 billion by 2030 from USD 26.58 billion in 2025, at a CAGR of 9.7% during the forecast period.

Browse 537 market data Tables and 59 Figures spread through 448 Pages and in-depth TOC on "Infectious Disease Diagnostics Market - Global Forecast to 2030"

Download PDF - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

The growth of the infectious disease diagnostics market is primarily driven by the increasing incidence & prevalence of infectious diseases globally, coupled with the growing emphasis on early detection and timely treatment. The emergence of novel pathogens, recurring outbreaks, and the threat of antimicrobial resistance have further highlighted the need for accurate and rapid diagnostic solutions. Advancements in diagnostic technologies, including molecular & point-of-care platforms, have significantly improved test performance, accessibility, and turnaround times. Additionally, healthcare expenditure growth, diagnostic infrastructure expansion in emerging economies, and supportive government initiatives to strengthen disease surveillance are contributing to the market growth.

By product & service, the reagents, kits, and consumables segment accounted for the largest share of the market in 2024.

By product & service, the market is segmented into reagents, kits, and consumables; instruments; and software & services. In 2024, the reagents, kits, and consumables segment accounted for the largest share of the market. The large share of this segment is attributed to the high volume of these products required for routine testing. Unlike instruments, consumable purchases are recurring, leading to consistent demand among end users. Additionally, their wide availability and critical role in test performance contribute to market growth further.

By sample type, the blood, serum, and plasma segment accounted for the largest share of the market in 2024.

The infectious disease diagnostics market has been segmented based on sample type into blood, serum, and plasma; urine; and other sample types. In 2024, the blood, serum, and plasma segment accounted for the largest share of the infectious disease diagnostics market, by sample type. These samples offer a rich & diverse source of diagnostic information for infectious diseases. They contain circulating DNA, RNA, proteins, and biomarkers, providing critical insights into numerous diseases and conditions. This abundance of biological data supports accurate diagnosis, helps track disease progression, and enables personalized treatment planning by healthcare professionals.

In 2024, North America accounted for the largest share of the market.

The infectious disease diagnostics market is segmented into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America accounted for the largest share of the market. The region's leadership is primarily driven by a well-established diagnostics landscape, with the US as the key contributor. Factors supporting this dominance include a robust healthcare infrastructure, a high burden of infectious diseases, and substantial investments in advanced diagnostic technologies and innovation.

The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Danaher Corporation (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Bio-Rad Laboratories, Inc. (US).

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.